Navigation Links
Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:10/22/2007

n patients with advanced solid tumors and in patients co-infected with HCV and HIV.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the protocol will not be approved, the risk that the company will experience delays or difficulties in enrolling patients in the study, and the risk that the results from this trial will not be consistent with the results of prior trials or pre-clinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and quarterly report on Form 10-Q for the quarter ended July 31, 2007. The company cautions investors not to place undue re
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 On Thursday, July ... the Dow Jones Industrial Average finished the day 0.42% lower ... 0.41%. The losses were broad based as eight out of ... Health Care Sector Index ended the day at 711.88, down ... one month. Investor-Edge has initiated coverage on the following equities: ...
(Date:7/11/2014)... 11, 2014 Show ... & Health Expo 2014 were a brand ... London , plus a ...          (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... )      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... National Institute of,Standards and Technology (NIST) has selected ... Commerce Department,s Advanced Technology Program,(ATP), a peer-reviewed competition. ... the early-phase Michigan biotechnology company developing,drug therapies to ... disorders. Velcura scientists have discovered a family ...
... YORK, Sept. 27 Immtech Pharmaceuticals,Inc. (Immtech) (Amex: ... Food and Drug,Administration of the People,s Republic of ... for conducting a Phase III clinical,trial with pafuramidine, ... Pneumocystis pneumonia (PCP). Pafuramidine is among the first,drugs ...
Cached Medicine Technology:NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease 2Chinese SFDA Grants Immtech Fast Track Status 2Chinese SFDA Grants Immtech Fast Track Status 3
(Date:7/11/2014)... Obese and overweight firefighters are not receiving ... according to new research from The University of ... National guidelines state that health care professionals (HCPs) ... a healthy weight. Firefighters have high rates of ... of line-of-duty deaths in firefighters. This study assessed ...
(Date:7/11/2014)... The Corn Farming industry ... on the heels of fresh biofuel demand. The Federal ... a larger share of their farmland to cultivating high-value ... required the mixing of 5.0% renewable content in gasoline ... United States created a key export market for Canadian ...
(Date:7/11/2014)... Reinberg HealthDay Reporter THURSDAY, ... protect children from the worldwide scourge of dengue fever was ... the vaccine only prevented dengue fever in 56 percent of ... shots, it protected more than 88 percent of them from ... to hospitalization, and sometimes death. "This vaccine has already ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... CA. Over the years Luke Bryan has been honored by ... he do well at award shows, but each summer, he hits ... tours of the genre and this summer is more of the ... to the popularity and success that is currently entitled to Luke ...
(Date:7/11/2014)... Riverside Health System became the first provider ... in late 2012 and now, in partnership with Williamsburg Landing, ... the Williamsburg and Newport News region. , Also known as ... to independent older adults who wish to remain in their ... of continuing care services as well as control over the ...
Breaking Medicine News(10 mins):Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
... not quintessentially masculine, women in their fertile phase are ... women paired with George Clooney types. But women ... to their partners, a recent study co-authored by a ... a man,s intelligence has no effect on the extent ...
... Residents of Cuyahoga County, and later Lorain County, will ... of a national resource for childhood growth and development. ... of children,s health ever conducted in the United States. ... The study will enroll women who are pregnant ...
... -- People over age 65 are at increased risk for ... study finds. Latent tuberculosis occurs when TB bacteria lurk ... has no symptoms of TB and is not contagious. However, ... cause tuberculosis, which can be fatal if it goes untreated. ...
... has received a boost from a surprising source: the 2009 ... 2009 H1N1 strain developed antibodies that are protective against a ... Medicine and the University of Chicago have found. The results ... Medicine . "Our data shows that infection with the ...
... one of today,s most exciting scientific and clinical areas. ... rulings by regulatory bodies or ethical controversies. These often ... ethicists, legislators, the media and the public. ESHRE,s ... of the world,s leading experts in reproductive medicine gather ...
... Race and ethnicity play major roles in whether people get ... much less likely to undergo colonoscopies than white people. Now, ... people live. Research by oncologist Dr. Thomas Semrad ... Center found that location makes a big difference in rates ...
Cached Medicine News:Health News:Men with macho faces attractive to fertile women, researchers find 2Health News:Men with macho faces attractive to fertile women, researchers find 3Health News:Case Western Reserve University School of Medicine launches the National Children's Study 2Health News:Treating Latent TB After 65 Raises Serious Side-Effect Risk 2Health News:Pandemic flu strain could point way to universal vaccine 2Health News:Pandemic flu strain could point way to universal vaccine 3Health News:ESHRE bridges East and West for its 2012 Congress in Istanbul 2Health News:Geography May Influence Colon Cancer Screening Rates 2
... Beta 200 ophthalmoscope, ... glare-free direct ophthalmoscope. Heine's ... patent #4,963,014) along with ... construction, make the Beta ...
... optics. The separation of illumination and observation ... system avoids corneal and iris reflex (Gullstrand-principle). ... the whole of the illuminated section of ... Conventional ophthalmoscopes often let you see only ...
... Beta 200S is the first ... combination of patented aspherical optics ... range of corrective lenses from ... single diopter steps. A perfectly-focused ...
With the unique automatic focus system, Autofoc 2 remains the instrument of choice for direct ophthalmoscopy. Includes XHL halogen bulb....
Medicine Products: